Dahan Michel 4
4 · Akebia Therapeutics, Inc. · Filed Mar 1, 2023
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2023-02-27$0.81/sh−10,090$8,205→ 289,927 total
Footnotes (2)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.
- [F2]Includes 1,500 shares of the Issuers common stock purchased on June 30, 2022, and 1,500 shares of the Issuers common stock purchased on December 30, 2022, each under the Issuer's 2014 Amended and Restated Employee Stock Purchase Plan.